炉石传说电竞之星直播平台

To the Editor: Khatri’s and Stuckey’s 1 article, Vertebral fractures after denosumab discontinuation for dental procedures: a consequence of distorted perceptions of risk , sums up the authors’ knowledge and experience of medication‐related osteonecrosis of the jaws (MRONJ) in the latter part of the title. They quote the risk of MRONJ as being very low and equal for denosumab and oral bisphosphonates. This is incorrect. The risk of MRONJ is 0.3%. 2 In our study we found the risk following extractions at 1.8%. 3 The recent 2022 update of the position paper on MRONJ 4 found that the risk with denosumab is an order of magnitude higher than for bisphosphonates.